GSK revenue and financials

GSK · NYSE · USD

Secondary listing. The primary listing is GSK · LSE (GBp)

$46.60Change from previous close: +0.11%Absolute change: +$0.05

Close · October 6, 2026

In the fiscal year ended December 2025, GSK reported revenue of £32.67B (+4.11% year over year). Net income was £5.72B, a net margin of 17.5%.

Annual revenue · 2025: £32.67B
  1. £27.89B2016
  2. £30.19B2017
  3. £30.82B2018
  4. £33.75B2019
  5. £24.35B2020
  6. £24.7B2021
  7. £29.32B2022
  8. £30.33B2023
  9. £31.38B2024
  10. £32.67B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+4.11%
2025 vs 2024
Net income growth
+121.98%
2025 vs 2024
Net margin
17.5%
2024: 8.2%

Financial data

Amounts in millions of GBP; per-share values in GBP; shares in millions.

Cash flow · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Operating cash flow2,6901,1412,2782,2222,0961,1452,3292,1541,1139583,1962,212
Depreciation and amortization223463-626738619823201951639549420579
Capital expenditure-328-221-573-311-256-208-544-305-302-248-486-299
Investing cash flow-789-1,466-933-1,531-625-1,144-1,119-731770-149268-491
Financing cash flow-2,149272-856-1,315-2,372858-842-1,240-1,584-1,060-3,592-1,762
Dividends paid-727-643-646-650-656-612-612-612-652-568-568-567
Share repurchases-308-326-252-317-561-247——————
Debt issued2731,202552-80.06452,0771,341———-1,409-615
Debt repaid-958-73.0-79.0-62.0-1,572-216-1,153-604-596-380-1,410-483
Effect of exchange rates-7.02.0-41.059.0-26.0-11.07.0-34.0-8.0-19.0-34.023.0
Net change in cash-212-51.0448-565-927848375149291-270-162-18.0
Free cash flow2,3629201,7051,9111,8409371,7851,8498117102,7101,913
Levered free cash flow1,0994852231,3853677501,9371,8875105793,0321,345